Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

By R. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. V. Van Poppel, E. Crawford. Journal of Urology, 2005

882 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Role of surgery and local therapy In the cytokine era, cytoreductive nephrectomy (CN) was recommended in patients with good PS [I, A] [36].”
EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “In ameta-analysis of two randomised studies comparing nephrectomy combined with immunotherapyversus immunotherapyonly, increased long-term survival was found in patients undergoing nephrectomy [39].”
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. (2022, background): “In the previous cytokine era, combined treatment with CN plus interferon-based immunotherapy versus interferon only showed greater survival for patients treated with CN [64].”
EAU guidelines on renal cell carcinoma: the 2010 update. (2010, background): “In a meta-analysis of two randomised studies comparing nephrectomy combined with immunotherapy versus immunotherapy only, increased long-term survival was found in patients undergoing nephrectomy [39].”
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “In the cytokine era, cytoreductive nephrectomy (CN) was recommended in patients with good PS [I, A] [36].”
Renal cell carcinoma (2017, background): “In the cytokine era, cytoreductive nephrectomy (CN) was recommended in patients with good PS [I, A] [36].”